607 related articles for article (PubMed ID: 24148764)
1. High-throughput screens identify microRNAs essential for HER2 positive breast cancer cell growth.
Leivonen SK; Sahlberg KK; Mäkelä R; Due EU; Kallioniemi O; Børresen-Dale AL; Perälä M
Mol Oncol; 2014 Feb; 8(1):93-104. PubMed ID: 24148764
[TBL] [Abstract][Full Text] [Related]
2. MicroRNA-143-5p Suppresses ER-Positive Breast Cancer Development by Targeting Oncogenic HMGA2.
Mansoori B; Kiani S; Mezajin AA; Zandi P; Banaie H; Rostamzadeh D; Cho WC; Duijf PHG; Mansoori B; Baradaran B
Clin Breast Cancer; 2023 Oct; 23(7):e480-e490.e3. PubMed ID: 37596147
[TBL] [Abstract][Full Text] [Related]
3. Differential expression of the miR-17-92 cluster and miR-17 family in breast cancer according to tumor type; results from the Norwegian Women and Cancer (NOWAC) study.
Moi L; Braaten T; Al-Shibli K; Lund E; Busund LR
J Transl Med; 2019 Oct; 17(1):334. PubMed ID: 31581940
[TBL] [Abstract][Full Text] [Related]
4. MiR-199b-5p targets HER2 in breast cancer cells.
Fang C; Zhao Y; Guo B
J Cell Biochem; 2013 Jul; 114(7):1457-63. PubMed ID: 23296799
[TBL] [Abstract][Full Text] [Related]
5. Involvement of miR-770-5p in trastuzumab response in HER2 positive breast cancer cells.
Noyan S; Gurdal H; Gur Dedeoglu B
PLoS One; 2019; 14(4):e0215894. PubMed ID: 31009516
[TBL] [Abstract][Full Text] [Related]
6. Survivin-targeting miR-542-3p overcomes HER3 signaling-induced chemoresistance and enhances the antitumor activity of paclitaxel against HER2-overexpressing breast cancer.
Lyu H; Wang S; Huang J; Wang B; He Z; Liu B
Cancer Lett; 2018 Apr; 420():97-108. PubMed ID: 29409974
[TBL] [Abstract][Full Text] [Related]
7. Posttranscriptional upregulation of HER3 by HER2 mRNA induces trastuzumab resistance in breast cancer.
Li X; Xu Y; Ding Y; Li C; Zhao H; Wang J; Meng S
Mol Cancer; 2018 Aug; 17(1):113. PubMed ID: 30068375
[TBL] [Abstract][Full Text] [Related]
8. Involvement of the Dysregulation of miR-23b-3p, miR-195-5p, miR-656-5p, and miR-340-5p in Trastuzumab Resistance of HER2-Positive Breast Cancer Cells and System Biology Approach to Predict Their Targets Involved in Resistance.
Rezaei Z; Sebzari A; Kordi-Tamandani DM; Dastjerdi K
DNA Cell Biol; 2019 Feb; 38(2):184-192. PubMed ID: 30702337
[TBL] [Abstract][Full Text] [Related]
9. A novel double-negative feedback loop between miR-489 and the HER2-SHP2-MAPK signaling axis regulates breast cancer cell proliferation and tumor growth.
Patel Y; Shah N; Lee JS; Markoutsa E; Jie C; Liu S; Botbyl R; Reisman D; Xu P; Chen H
Oncotarget; 2016 Apr; 7(14):18295-308. PubMed ID: 26918448
[TBL] [Abstract][Full Text] [Related]
10. miR-342-5p as a Potential Regulator of HER2 Breast Cancer Cell Growth.
Lindholm EM; Leivonen SK; Undlien E; Nebdal D; Git A; Caldas C; Børresen-Dale AL; Kleivi K
Microrna; 2019; 8(2):155-165. PubMed ID: 30520388
[TBL] [Abstract][Full Text] [Related]
11. Meta-microRNA Biomarker Signatures to Classify Breast Cancer Subtypes.
Oztemur Islakoglu Y; Noyan S; Aydos A; Gur Dedeoglu B
OMICS; 2018 Nov; 22(11):709-716. PubMed ID: 30388053
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA in combination with HER2-targeting drugs reduces breast cancer cell viability in vitro.
Normann LS; Aure MR; Leivonen SK; Haugen MH; Hongisto V; Kristensen VN; Mælandsmo GM; Sahlberg KK
Sci Rep; 2021 May; 11(1):10893. PubMed ID: 34035375
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer.
Lowery AJ; Miller N; Devaney A; McNeill RE; Davoren PA; Lemetre C; Benes V; Schmidt S; Blake J; Ball G; Kerin MJ
Breast Cancer Res; 2009; 11(3):R27. PubMed ID: 19432961
[TBL] [Abstract][Full Text] [Related]
14. Cell specific tumor suppressor effect of Hsa-miR-1226-3p through downregulation of HER2, PIK3R2, and AKT1 genes.
Mohamadzade Z; M Soltani B; Ghaemi Z; Hoseinpour P
Int J Biochem Cell Biol; 2021 May; 134():105965. PubMed ID: 33675995
[TBL] [Abstract][Full Text] [Related]
15. Up-regulation of miR-21 by HER2/neu signaling promotes cell invasion.
Huang TH; Wu F; Loeb GB; Hsu R; Heidersbach A; Brincat A; Horiuchi D; Lebbink RJ; Mo YY; Goga A; McManus MT
J Biol Chem; 2009 Jul; 284(27):18515-24. PubMed ID: 19419954
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA-510 promotes cell and tumor growth by targeting peroxiredoxin1 in breast cancer.
Guo QJ; Mills JN; Bandurraga SG; Nogueira LM; Mason NJ; Camp ER; Larue AC; Turner DP; Findlay VJ
Breast Cancer Res; 2013; 15(4):R70. PubMed ID: 23971998
[TBL] [Abstract][Full Text] [Related]
17. Modulation of MicroRNA-194 and cell migration by HER2-targeting trastuzumab in breast cancer.
Le XF; Almeida MI; Mao W; Spizzo R; Rossi S; Nicoloso MS; Zhang S; Wu Y; Calin GA; Bast RC
PLoS One; 2012; 7(7):e41170. PubMed ID: 22829924
[TBL] [Abstract][Full Text] [Related]
18. HER2-intronic miR-4728-5p facilitates HER2 expression and accelerates cell proliferation and migration by targeting EBP1 in breast cancer.
Zhou Y; Yuan Y; Li L; Wang X; Quan Y; Liu C; Yu M; Hu X; Meng X; Zhou Z; Zhang CY; Chen X; Liu M; Wang C
PLoS One; 2021; 16(2):e0245832. PubMed ID: 33529238
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic silencing of miR-375 induces trastuzumab resistance in HER2-positive breast cancer by targeting IGF1R.
Ye XM; Zhu HY; Bai WD; Wang T; Wang L; Chen Y; Yang AG; Jia LT
BMC Cancer; 2014 Feb; 14():134. PubMed ID: 24571711
[TBL] [Abstract][Full Text] [Related]
20. MiR-4728-3p could act as a marker of HER2 status.
Li H; Zhou X; Zhu J; Cheng W; Zhu W; Shu Y; Liu P
Cancer Biomark; 2015; 15(6):807-14. PubMed ID: 26406406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
